EMA Reinstates GMP Certificate for Ranbaxy's Toansa Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Reinstates GMP Certificate for Ranbaxy's Toansa Facility


European Medicines Agency regulators have announced that the agency will reinstate the GMP certificate for Ranbaxy’s Toansa, India, manufacturing facility, following an assessment of reported non-compliance.

Although the assessment showed that there were a number of GMP deficiencies at the site, assessment of all available information reassured European regulators that there has been no risk to public health from these deficiencies, EMA reported in a press statement.

European regulators considered the corrective measures put in place by the company and were satisfied that the measures are sufficient to ensure GMP-compliant manufacture of products at the site.

The assessment followed an inspection by the US FDA, which revealed areas of non-compliance with GMP at the site. In response, the European medicines regulatory network sent inspectors from Germany, Ireland, and the UK, who were joined by inspectors from Switzerland and Australia to undertake an unannounced international inspection of the site.

The GMP inspection concluded that appropriate corrective and preventive measures have been put in place by the manufacturer. The inspection team concluded that there was no evidence that any medicines on the EU market that have an active pharmaceutical ingredient manufactured in Toansa were of unacceptable quality or presented a risk to the health of patients taking them. This conclusion was supported by tests of samples of these medicines, all of which met the correct quality specifications, EMA reports

European regulatory authorities have identified the need to keep the Toansa site under close supervision and this will be done in collaboration with India and other regulatory authorities around the globe.

The European Union (EU) authorities will reinstate the GMP certificate, which was suspended in January 2014. The certificate will be re-entered into EudraGMDP, the EU database that contains GMP certificates.

Source: European Medicines Agency

 


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here